Why Hims & Hers Health Stock Is Plummeting Today

Shares of Hims & Hers Health (NYSE: HIMS) are falling on Friday. The company's stock lost 23.2% as of 1 p.m. ET and lost as much as 26.1% earlier in the day. The move comes as the S&P 500 lost 1% and the Nasdaq Composite lost 1.3%.

Hims & Hers, one of the most popular telehealth services in the world, is in danger of losing one of its central revenue sources.

Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More »

Ozempic is no longer in short supply

The U.S. Food and Drug Administration (FDA) removed semaglutide injection products like the blockbuster drugs Ozempic and Wegovy from its shortage list. The FDA will now begin taking action against "compounders" -- companies that were able to make generic versions of semaglutide drugs due to their shortage -- in the next 60 to 90 days. Only brand-name semaglutide products will be available moving forward unless another shortage occurs.

A big hit to Hims & Hers

Though it doesn't compound them itself, Hims & Hers saw its sales explode over the last year driven in part by its ability to sell compounded semaglutide products through its platform. The FDA's decision means a marked reduction in revenue for the company. The news also comes just as the company announced it had purchased a peptide facility that would have allowed it to compound these medications itself.

However, despite the bad news, Hims & Hers Health's CEO remains hopeful that there are many other personalized weight loss products it can provide through this facility that will continue to drive sales.

Don’t miss this second chance at a potentially lucrative opportunity

Ever feel like you missed the boat in buying the most successful stocks? Then you’ll want to hear this.

On rare occasions, our expert team of analysts issues a “Double Down” stock recommendation for companies that they think are about to pop. If you’re worried you’ve already missed your chance to invest, now is the best time to buy before it’s too late. And the numbers speak for themselves:

• Nvidia: if you invested $1,000 when we doubled down in 2009, you’d have $363,307!*
• Apple: if you invested $1,000 when we doubled down in 2008, you’d have $46,607!*
• Netflix: if you invested $1,000 when we doubled down in 2004, you’d have $552,526!*

Right now, we’re issuing “Double Down” alerts for three incredible companies, and there may not be another chance like this anytime soon.

Learn more »

*Stock Advisor returns as of February 21, 2025

Johnny Rice has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.